Dermatology

Kristen Whitney, DO, FAAD, dermatologist within the Allegheny Health Network, discusses advancements in dermoscopy, predicting that emerging technologies and artificial intelligence (AI) will improve dermatologists' efficiency in monitoring and diagnosing skin conditions.

In this discussion, panelists offer their final thoughts.

Patients with vitiligo and psychosocial comorbidities face significantly higher overall health care utilization and costs, although their vitiligo-related expenditures remain similar to those without such comorbidities.

In this discussion, panelists explore the potential role of new Bruton tyrosine kinase inhibitors in the treatment landscape for chronic spontaneous urticaria (CSU), evaluating their stages of development and expected impact on treatment algorithms, while also considering future changes in coverage and payer strategies with the emergence of new therapies.

A panel of experts discuss the clinical trials of dupilumab, the resultant data, and the response of the FDA when approval was requested.

The FDA has approved nemolizumab (Nemluvio; Galderma) to treat patients with prurigo nodularis based on successful phase III trials demonstrating significant reductions in itch and sleep disturbances.

Challenges in choosing between corticosteroids and noncorticosteroids for pediatric dermatologic conditions include balancing efficacy, safety, compliance, and long-term management while considering the specific needs and risks of each child.

Steve Feldman, MD, PhD, of Wake Forest University School of Medicine, discusses how adverse event risks influence atopic dermatitis treatment selection and highlights promising new therapies offering effective itch control with minimal side effects.

A panel of experts discuss the key updates needed in CSU guidelines, as they have not been updated since 2014.

Panelists discuss how 30%-50% of patients with chronic spontaneous urticaria remain symptomatic despite treatment, examining the impact of treatment burdens, the limitations of targeting the IgE pathway, and the need for new therapies addressing the IgG pathway.

This new study confirms the noninferiority of extended dosing intervals for psoriasis control in super responders.

Steve Feldman, MD, PhD, of Wake Forest University School of Medicine, considers dupilumab the "gold standard" for itch control in patients with atopic dermatitis due to its minimal adverse effects.

Posters presented at the Society for Pediatric Dermatology Annual Meeting shed new light on pediatric hair loss, including the rising prevalence of androgenetic alopecia in children, the potential of artificial intelligence to assess hair loss severity, and the long-term safety of ritlecitinib for treating alopecia areata in adolescents.

Steve Feldman, MD, PhD, of Wake Forest University School of Medicine, discusses various effective treatments for alleviating itch in patients with atopic dermatitis (AD), including dupilumab and Janus kinase (JAK) inhibitors.

Two posters presented at the Society for Pediatric Dermatology Annual Meeting explored common health conditions linked to childhood alopecia areata and the effectiveness of dupilumab treatment in children with both alopecia areata and atopic dermatitis.

Patients with atopic dermatitis who use oral corticosteroids for more than 90 days have a slightly increased risk of adverse events like myocardial infarction and hyperlipidemia.

The Society for Pediatric Dermatology (SPD) Annual Meeting focused on different aspects of pediatric dermatology, including topical treatments, technology, and misinformation.

A literature review found a link between COVID-19 vaccination and alopecia, with most cases experiencing hair loss within 1 month after the first dose. However, the small sample size and limited data call for further investigation.

Timothy Caulfield, JD, research director of the Health Law Institute at the University of Alberta, discusses strategies for building trust, overcoming cultural and language barriers, and enhancing interdisciplinary collaboration in pediatric dermatology at the Society of Pediatric Dermatology conference.

Experts in dermatology presented ways in which biologic therapies can be given and the duration of treatment when used in pediatric patients with skin conditions.

Posters presented at the Society for Pediatric Dermatology Annual Meeting found that pediatric deroofing can lead to patient satisfaction later in life.

Updates in nonsteroidal topical therapies were presented during a session at the Society for Pediatric Dermatology Annual Meeting.

A presentation at the Society for Pediatric Dermatology Annual Conference discussed how to use generative artificial intelligence (AI) to improve processes while working in the dermatology space.

The Society for Pediatric Dermatology (SPD) Annual Meeting featured a new debates segment where experts in the field discussed preferred strategies for the treatment of pediatric skin conditions.

Twice-daily application of 1.5% ruxolitinib cream was found to be effective in children and adolescents with atopic dermatitis and vitiligo.

Today, the FDA approved roflumilast cream 0.15% (Zorvye; Arcutis Biotherapeutics) for the treatment of mild to moderate atopic dermatitis in patients 6 years and older.

Patients with vitiligo have a higher genetic risk of developing rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

The annual meeting will take place in Toronto July 11-15, 2024.

Iltefat Hamzavi, MD, outlines comorbidities associated with hidradenitis suppurativa and discusses best practices for coordinating care between specialists.

An expert on hidradenitis suppurativa describes the characteristics for each of the 3 stages in the Hurley staging system and how they inform treatment decisions.